N-acetyl Semax comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
In physics, a vapor (American English) or vapour (Commonwealth English; see spelling differences) is a substance in the gas phase at a temperature lower than its critical temperature, which means that the vapor can be condensed to a liquid by increasing the pressure on it without reducing the temperature of the vapor. A vapor is different from an aerosol. An aerosol is a suspension of tiny particles of liquid, solid, or both within a gas. For example, water has a critical temperature of 647 K (374 °C; 705 °F), which is the highest temperature at which liquid water can exist at any pressure. In the atmosphere at ordinary temperatures gaseous water (known as water vapor) will condense into a liquid if its partial pressure is increased sufficiently. A vapor may coexist with a liquid (or a solid). When this is true, the two phases will be in equilibrium, and the gas-partial pressure will be equal to the equilibrium vapor pressure of the liquid (or solid).
Julia Nickson is a film actress. She first came to the attention of worldwide audiences in the 1985 action film Rambo: First Blood Part II, starring Sylvester Stallone. She also appeared in the 2004 film Ethan Mao and in the 2008 independent film Half-Life.
==== War poetry ==== Thomas's horror of war, foreshadowed in some of his poems of the 1930s and fuelled by his lived experience of the bombing raids and fire storms of the Blitz in London, received further expression in his poems of the war period. These include elegies for an elderly man—Among Those Killed in a Dawn Raid Was a Man Aged a Hundred (1941)—and for child victims of incendiary bombing raids in Ceremony After a Fire Raid (1944) and A Refusal to Mourn the Death, by Fire, of a Child in London (1945). They were collected in Deaths and Entrances, the fourth volume of his poetry, published in 1946. The sentiments expressed in his war poems were, according to Walford Davies, representative of "the real temper of the British people of the time—the resilience and the guts".
=== Suppression of the pro-Alid groups === Mu'awiya died in 680 and was succeeded by his son Yazid I. Mu'awiya's designation of his son was an unprecedented act and shocked many in the Muslim community, particularly the Arab nobility of Kufa. They long sympathized with Caliph Ali, Mu'awiya's former rival, and Ali's family. One of Ali's sons, Husayn dispatched his cousin Muslim ibn Aqil to Kufa to set the stage for Husayn's accession to the caliphate. Ibn Aqil garnered significant support and was hosted by a prominent pro-Alid nobleman. Ubayd Allah became aware of Ibn Aqil's activities, prompting the latter to launch a premature assault against the governor. Ubayd Allah was holed up in his palace, but thirty men from his shurta (security forces) fended off Ibn Aqil's partisans, while he persuaded many Kufan noblemen to back him against Ibn Aqil, who was abandoned by his supporters and slain on 10 September 680. Husayn had already been en route to Kufa from Medina when he received news of Ibn Aqil's execution. Ubayd Allah was prepared for Husayn's arrival and sent troops to intercept him. They prevented Husayn and his small retinue from reaching the watered areas of the province. The two sides negotiated for weeks, but Ubayd Allah refused Husayn entry into Kufa or return to Arabia while Husayn refused to recognize Yazid's caliphate. In the end, a short battle was fought at Karbala on 10 October 680, in which Husayn and nearly all of his partisans were slain.
Sources: en.wikipedia.org
=== Marfan syndrome === TGF-β signaling also likely plays a major role in the pathogenesis of Marfan syndrome, a disease characterized by disproportionate height, arachnodactyly, ectopia lentis and heart complications such as mitral valve prolapse and aortic enlargement increasing the likelihood of aortic dissection. While the underlying defect in Marfan syndrome is faulty synthesis of the glycoprotein fibrillin I, normally an important component of elastic fibers, it has been shown that the Marfan syndrome phenotype can be relieved by addition of a TGF-β antagonist in affected mice. This suggests that while the symptoms of Marfan syndrome may seem consistent with a connective tissue disorder, the mechanism is more likely related to reduced sequestration of TGF-β by fibrillin.
=== Soft tissue rheumatism === Local diseases and lesions affecting the joints and structures around the joints including tendons, ligaments capsules, bursae, stress fractures, muscles, nerve entrapment, vascular lesions, and ganglia. For example:
== Clinical significance == The inherited disease, dystrophic epidermolysis bullosa, is caused by recessive or dominant mutations in COL7A1. Recessive dystrophic epidermolysis bullosa, the most severe type of epidermolysis bullosa, has two subtypes, generalized intermediate and generalized severe, which have been linked to different mutations in the COL7A1 gene. Recessive dystrophic epidermolysis bullosa, generalized intermediate, is caused primarily by missense, in-frame, and splice-site mutations on one allele. The generalized severe subtype may be caused by premature termination codons in both alleles. These mutations cause little to no expression of collagen VII, which manifests primarily as generalized blistering in the skin and mucosal membranes. This blistering may also lead to several other complications, such as eye abrasions, esophageal stricture, deformity of the hands and feet, and squamous cell carcinoma, among others. Dominant dystrophic epidermolysis bullosa is most often caused by missense mutations, especially glycine substitutions in the collagenous domain. The symptoms of dominant dystrophic epidermolysis bullosa are less severe than those of the recessive types, with mild blistering and loss of nails. Epidermolysis bullosa acquisita involves an autoimmune reaction to this form of collagen. Beremagene geperpavec (Vyjuvek), is a gene therapy indicated for the treatment of wounds for people with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
The Balfour Declaration (2 November 1917) was a public statement issued by the British Government in 1917 during the First World War announcing its support for the establishment of a "national home for the Jewish people" in Palestine, then an Ottoman region with a small Jewish minority among an overwhelming Arab majority, mostly Muslim but also including Christians. The declaration was contained in a letter dated 2 November 1917 from Arthur Balfour, the British foreign secretary, to Lord Rothschild, a leader of the British Jewish community, for transmission to the Zionist Federation of Great Britain and Ireland. The text of the declaration was published in the press on 9 November 1917. Following Britain's declaration of war on the Ottoman Empire in November 1914, it had begun to consider the future of Palestine. Within two months a memorandum was circulated to the War Cabinet by a Zionist member, Herbert Samuel, proposing support of Zionist ambitions in order to gain the support of Jews in the current war. A committee was established in April 1915 by British prime minister H. H. Asquith to determine policy towards the Ottoman Empire including Palestine. Asquith, who had favoured post-war reform of the Ottoman Empire, resigned in December 1916; his replacement David Lloyd George favoured partition of the Empire. The first negotiations between the British and the Zionists took place at a conference on 7 February 1917 that included Sir Mark Sykes and the Zionist leadership.
=== Cardiovascular disease === Metallothionein (MT) is an indirect redox balance regulator which regulates nuclear factor red blood cell 2-related factor 2 (Nrf2) in the body. However, MT plays an important role in the anti-injury protection of the cardiovascular system, mainly in its inhibitory effect on ischemia-reperfusion injury. Also, the MT activation of the Nrf2 mediates intermittent hypoxia (IH) cardiomyopathy protection. Transgenic mice with a deletion of any Nrf2 gene (Nrf2-KO) are highly susceptible to the cardiovascular effects of intermittent hypoxia (IH) via cardiac oxidative damage, inflammation, fibrosis, and dysfunction. Moreover, the specific overexpression in cardiomyocytes of Nrf2 (Nrf2-TG) in transgenic mice[KC1] is impervious to cardiac oxidative damage, inflammation, fibrosis, and dysfunction caused by intermittent hypoxia (IH)[KC2] . In response to IH, Nrf2 and its downstream antioxidants are strongly MT-dependent Nrf2 and may [KC3] act as a compensatory response to IH exposure by up-regulating MT (downstream antioxidant target genes) to protect the heart. Prolonged exposure to IH reduces the binding of Nrf2 factor to the MT promoter gene, thereby inhibiting MT translation and expression. Moreover, a complex PI3K/Akt/GSK3B/Fyn signaling network provides cardio protection against IH when Nrf2 or MT is overexpressed in the heart. By activating the PI3K/Akt/GSK3B/Fyn signaling pathway, MT increaseNrf2 expression and transcriptional function in response to IH exposure.
Sources: en.wikipedia.org
== Structure == The structure of the human PLC has been determined using single-particle electron cryo-microscopy (cryo-EM). The PLC, measuring 150 Å by 150 Å and with a total height of 240 Å, is organized around the Transporter associated with Antigen Processing (TAP). It includes molecules such as tapasin, calreticulin, ERp57, and Major Histocompatibility Complex class I (MHC-I), arranged in a pseudo-symmetric pattern.
African histoplasmosis Alternariosis Antibiotic candidiasis (iatrogenic candidiasis) Black piedra Candidal intertrigo Candidal onychomycosis Candidal paronychia Candidal vulvovaginitis Candidid Chromoblastomycosis (chromomycosis, cladosporiosis, Fonseca's disease, Pedroso's disease, phaeosporotrichosis, verrucous dermatitis) Chronic mucocutaneous candidiasis Coccidioidomycosis (California disease, desert rheumatism, San Joaquin Valley fever, valley fever) Congenital cutaneous candidiasis Cryptococcosis Dermatophytid Diaper candidiasis Disseminated coccidioidomycosis (coccidioidal granuloma) Distal subungual onychomycosis Entomophthoromycosis Erosio interdigitalis blastomycetica Favus Fungal folliculitis (majocchi granuloma) Fusariosis Geotrichosis Granuloma gluteale infantum Histoplasmosis (cave disease, Darling's disease, Ohio Valley disease, reticuloendotheliosis) Hyalohyphomycosis Kerion Lobomycosis (keloidal blastomycosis, lacaziosis, Lobo's disease) Mucormycosis Mycetoma (Madura foot, maduromycosis) North American blastomycosis (blastomycetic dermatitis, blastomycosis, Gilchrist's disease) Onychomycosis (dermatophytic onychomycosis, ringworm of the nail, tinea unguium) Oral candidiasis (thrush) Otomycosis Perianal candidiasis Perlèche (angular cheilitis) Phaeohyphomycosis Piedra (trichosporosis) Pityrosporum folliculitis Primary cutaneous aspergillosis Primary cutaneous coccidioidomycosis Primary cutaneous histoplasmosis Primary pulmonary coccidioidomycosis Primary pulmonary histoplasmosis Progressive disseminated histoplasmosis Proximal subungual onychomycosis Rhinosporidiosis South American blastomycosis (Brazilian blastomycosis, paracoccidioidal granuloma, paracoccidioidomycosis) Sporotrichosis (rose-gardener's disease) Systemic candidiasis Tinea barbae (barber's itch, ringworm of the beard, tinea sycosis) Tinea capitis (herpes tonsurans, ringworm of the hair, ringworm of the scalp, scalp ringworm, tinea tonsurans) Tinea corporis (ringworm, tinea circinata, tinea glabrosa) Tinea corporis gladiatorum Tinea cruris (crotch itch, eczema marginatum, gym itch, jock itch, ringworm of the groin) Tinea faciei Tinea imbricata (tokelau) Tinea incognito Tinea manuum Tinea nigra (superficial phaeohyphomycosis, tinea nigra palmaris et plantaris) Tinea pedis (athlete's foot, ringworm of the foot) Tinea versicolor (dermatomycosis furfuracea, pityriasis versicolor, tinea flava) Trichophyton mentagrophytes VII (TMVII) (an emerging sexually transmitted tinea of the genitals, buttocks, face, trunk, and extremities) White piedra White superficial onychomycosis Zygomycosis (phycomycosis)
A number of drug interactions can occur between MDMA and other drugs, including serotonergic drugs. MDMA also interacts with drugs which inhibit CYP450 enzymes, like ritonavir (Norvir), particularly CYP2D6 inhibitors. Life-threatening reactions and death have occurred in people who took MDMA while on ritonavir. Bupropion, a strong CYP2D6 inhibitor, has been found to increase MDMA exposure with administration of MDMA. Concurrent use of MDMA with certain other serotonergic drugs can result in a life-threatening condition called serotonin syndrome. Severe overdose resulting in death has also been reported in people who took MDMA in combination with certain monoamine oxidase inhibitors (MAOIs), such as phenelzine (Nardil), tranylcypromine (Parnate), or moclobemide (Aurorix, Manerix). Serotonin reuptake inhibitors (SRIs) such as citalopram (Celexa), duloxetine (Cymbalta), fluoxetine (Prozac), and paroxetine (Paxil) have been shown to block most of the subjective effects of MDMA. Norepinephrine reuptake inhibitors (NRIs) such as reboxetine (Edronax) have been found to reduce emotional excitation and feelings of stimulation with MDMA but do not appear to influence its entactogenic or mood-elevating effects. MDMA induces the release of monoamine neurotransmitters and thereby acts as an indirectly acting sympathomimetic and produces a variety of cardiostimulant effects. It dose-dependently increases heart rate, blood pressure, and cardiac output.
With a $30–45 million production budget, filming began on 12 November 2010 in Cape Town and took approximately 13 weeks, with second unit photography occurring over seven weeks. Filming locations included Johannesburg and Cape Town Film Studios (Dredd was the first project filmed at the studio). The project involved a majority of Cape Town crew members and about 40 imported crew. The producers chose to film in South Africa because of the lowered cost of employing cast and crew compared to locations in Europe and North America, and government incentives that offered to rebate up to 25% of the production costs. The film was shot digitally and primarily in 3D using RED MX, SI2K and Phantom Flex high-speed cameras for the Slo-Mo sequences, producing 4,000 frames per second. Multiple camera rigs were used. Some 2D elements were converted to 3D in post-production. DNA Films' co-founder Andrew Macdonald engaged cinematographer Anthony Dod Mantle to manage the shoot; it was the first time Mantle had worked with 3D. The filmmakers wanted Dredd to have a realistic, visceral look, and drew inspiration from crime and gangster films. For scenes conveying the time and space altering effects of Slo-Mo, Mantle aimed to create images that would be beautiful but disorienting. Mega-City One and its high-rise towers were created in Cape Town Film Studios. Finding a suitable set for the expansive Peach Trees atrium proved difficult, and the producers did not want to build an expensive set.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.